Recently, experts have settled in the Academician Workstation of Fosun Pharma, including Professor Jiang Zhihong, Vice President of Macau University of Science and Technology. Professor Jiang Zhihong is an internationally renowned natural pharmaceutical chemist, studying fields such as natural pharmaceutical chemistry, metabolomics, quality standard of traditional Chinese medicine (TCM) and bioorganic chemistry.

On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association, undertaken by Shanghai Biopharmaceutics Industry Association, Fosun International Limited and Fosun Pharma, and supported by Shanghai Municipal Health Commission, Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Medical Products Administration.

Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.

In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.

In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.

 In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumours in an oral presentation.

On September 5, the awarding ceremony of the 4th "China Translational Medicine Award" was held in Beijing. Dr. Aimin Hui, Fosun Pharma's executive president, president of global R&D, and chief medical officer, was granted the 4th "China Translational Medicine Award - International Collaboration".

On June 19, 2021, the 27th Annual Meeting of Chinese Society of Dermatology (CSD) of Chinese Medical Association (CMA) was successfully held in Xi'an. During the meeting, a symposium on Han Da Yuan^® (Adalimumab Injection), Fosun Pharma's first biologics indicated for autoimmune disease, was grandly broadcast. For the symposium, Professor Xinghua Gao, the next president of the CMACSD and the vice president of the First Hospital of China Medical University, was invited to serve as the chairman, and Professor Yuzhen Li, from the Second Affiliated Hospital of Harbin Medical University, also a standing committee member of the CMACSD, was invited to serve as the speaker.